These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 31672443)

  • 1. Fibroblast growth factor 21 in non-alcoholic fatty liver disease.
    Tucker B; Li H; Long X; Rye KA; Ong KL
    Metabolism; 2019 Dec; 101():153994. PubMed ID: 31672443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease.
    Su X; Kong Y; Peng D
    Clin Chim Acta; 2019 Nov; 498():30-37. PubMed ID: 31419414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
    Liu J; Xu Y; Hu Y; Wang G
    Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice.
    Rusli F; Deelen J; Andriyani E; Boekschoten MV; Lute C; van den Akker EB; Müller M; Beekman M; Steegenga WT
    Sci Rep; 2016 Jul; 6():30484. PubMed ID: 27470139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
    Tillman EJ; Rolph T
    Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
    Alisi A; Ceccarelli S; Panera N; Prono F; Petrini S; De Stefanis C; Pezzullo M; Tozzi A; Villani A; Bedogni G; Nobili V
    PLoS One; 2013; 8(6):e67160. PubMed ID: 23840612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease.
    Waluga M; Kukla M; Zorniak M; Kajor M; Liszka L; Dyaczynski M; Kowalski G; Zadlo D; Waluga E; Olczyk P; Buldak RJ; Berdowska A; Hartleb M
    J Physiol Pharmacol; 2017 Jun; 68(3):363-374. PubMed ID: 28820393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.
    Wu YK; Ren ZN; Zhu SL; Wu YZ; Wang G; Zhang H; Chen W; He Z; Ye XL; Zhai QX
    Acta Pharmacol Sin; 2022 Jun; 43(6):1473-1483. PubMed ID: 34654875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of fibroblast growth factor 21 in non-alcoholic fatty liver disease in guinea pigs.
    Klaebel JH; Lykkesfeldt J; Tveden-Nyborg P
    Basic Clin Pharmacol Toxicol; 2022 Mar; 130(3):385-393. PubMed ID: 35014168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
    Woolsey SJ; Beaton MD; Mansell SE; Leon-Ponte M; Yu J; Pin CL; Adams PC; Kim RB; Tirona RG
    Mol Pharmacol; 2016 Oct; 90(4):437-46. PubMed ID: 27482056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease.
    Kim HY; Kwon WY; Park JB; Lee MH; Oh YJ; Suh S; Baek YH; Jeong JS; Yoo YH
    FASEB J; 2020 Sep; 34(9):12354-12366. PubMed ID: 32721044
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Long X; Liu D; Gao Q; Ni J; Qian L; Ni Y; Fang Q; Jia W; Li H
    Front Endocrinol (Lausanne); 2021; 12():773340. PubMed ID: 35035378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease.
    Chikamatsu M; Watanabe H; Shintani Y; Murata R; Miyahisa M; Nishinoiri A; Imafuku T; Takano M; Arimura N; Yamada K; Kamimura M; Mukai B; Satoh T; Maeda H; Maruyama T
    J Control Release; 2023 Mar; 355():42-53. PubMed ID: 36690035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
    Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease.
    Tucker B; McClelland RL; Allison MA; Budoff MJ; Wu BJ; Barter PJ; Rye KA; Ong KL
    Atherosclerosis; 2020 Apr; 299():38-44. PubMed ID: 32220662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis.
    Verzijl CRC; Van De Peppel IP; Struik D; Jonker JW
    Expert Opin Investig Drugs; 2020 Feb; 29(2):125-133. PubMed ID: 31899984
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis.
    Zarei M; Pizarro-Delgado J; Barroso E; Palomer X; Vázquez-Carrera M
    Trends Pharmacol Sci; 2020 Mar; 41(3):199-208. PubMed ID: 31980251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
    J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.
    Bao L; Yin J; Gao W; Wang Q; Yao W; Gao X
    Br J Pharmacol; 2018 Aug; 175(16):3379-3393. PubMed ID: 29859019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease.
    Wu G; Li H; Fang Q; Zhang J; Zhang M; Zhang L; Wu L; Hou X; Lu J; Bao Y; Jia W
    Sci Rep; 2017 Jul; 7(1):5095. PubMed ID: 28698650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.